Innovus Pharmaceuticals, Inc. (OTCQB: INNV) - Breaking News - January 24, 2018

Innovus Pharma Signs Exclusive License and Distribution Agreement with Lavasta Pharma for ProstaGorx® in Certain Middle Eastern and North African Countries

The Company to Receive an Upfront Payment plus Transfer Price on Minimum Annual Purchases Requirements

SAN DIEGO--January 24, 2018 -- Innovus Pharmaceuticals, Inc. (OTCQB: INNV) ("Innovus Pharma" or the “Company”), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today the signing of an exclusive license and distribution agreement with Lavasta Pharma FZ-LLC, a company based in Dubai (“Lavasta”) for the commercialization of ProstaGorx® in the Kingdom of Saudi Arabia, Algeria, Egypt, the United Arab Emirates, Lebanon, Jordan, Kuwait, Morocco, Tunisia, Bahrain, Oman, Qatar, and Turkey, among other countries. Under the agreement, Innovus Pharma will receive an up-front license payment, will sell the products to Lavasta at set supply prices and Lavasta has certain minimum annual purchase requirements.

“We are pleased to expand our international exports of our products through the introduction of our ProstaGorx® product in the Middle East and North Africa regions through this partnership with Lavasta,” said Innovus Pharma CEO, Dr. Bassam Damaj. “Lavasta is our 19h distribution partner for our products outside the United States and represents our second major partnership to sell one of our core U.S. products abroad,” said Innovus CEO Dr. Bassam Damaj. “This partnership is one more step towards achieving our 2018 corporate goals for expanded revenue and profitability from our many international distributors,” continued Dr. Damaj.

“We are excited to introduce ProstaGorx® to many countries throughout the Middle East. We believe this product meets large unmet needs in the region and we look forward to partnering with Innovus Pharma here through the use of our extensive marketing channels and sales forces in these countries,” said Tara Banasi, President of Lavasta.

About ProstaGorx® and Prostate Health

Prostate health issues affect millions of men and it is important to offer a natural, clinically tested, alternative product with a potentially approved claim for urologic symptoms of BPH. With multiple published clinical trials, ProstaGorx® ingredients have been shown to:

1. Work with the prescription drug finasteride to reduce actual prostate weight;
2. Regulate DHT production and hormones that influence prostate volume;
3. Clinically reduce nocturia, and improve prostate symptoms in men with BPH or prostatitis;
4. Clinically reduce overall rate of progression of prostate cancer in men; and
5. Decrease serum PSA levels, suppression of tumor growth and support urinary function.

An estimated 50% of men have histologic evidence of BPH by age 50 and 75% by age 80; in 40–50% of these men, BPH becomes clinically significant] BPH was one of the ten most common, and costly, diseases in men older than 50 years of age in a recent study in the United States.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.fluticare.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.allervarx.com; www.apaez.com; and www.prostagorx.com.
About Lavasta Pharma

Lavasta Pharma is a multi-specialty health care company focused on representing and commercializing innovative pharmaceuticals and over-the-counter consumer products that enable people to live life to its greatest potential. The company’s services currently extend to cover the region of Africa, Middle East and Turkey.

Lavasta Pharma has a regional team that manages the strategic execution of commercial operations across the AFMET region with a sales force team on the ground of 150+ across the region.

Lavasta Pharma has 2 main affiliated companies: (a) Lavasta Pharma FZ-LLC in Dubai, UAE that serves as the main commercial hub for the AFMET Region and (b) Lavasta Pharma LLC- UK in London, UK that serves as the Marketing Authorization and Intellectual Property holding entity.

Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to successfully commercialize ProstaGorx® and others in certain Middle Eastern and North African countries and elsewhere and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
# # #
Contact:
James S. Painter III
Emerging Markets Consulting, LLC
Tel: 407 340 0226
jamespainter@emergingmarketsllc.com
Source: Innovus Pharmaceuticals, Inc.

Innovus Pharma Announces Official Launch of its Amazon®, Walmart®, eBay® and Wish® On-Line Stores with a Combined 116 Product SKUs

SAN DIEGO--January 18, 2018 -- Innovus Pharmaceuticals, Inc. (OTCQB: INNV) ("Innovus Pharma" or the “Company”), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, today announced the official launch of its Amazon®, Walmart®, eBay® and Wish® on-line stores in the United States with a combined 116 Company product SKUs. As part of this on-line product distribution, the Company also secured worldwide non-exclusive rights to sell two primary products from Antiaging Systems, Ltd.: Can-C™ and Melatonin (MZS™).

The launch of the U.S. on-line stores adds to Innovus Pharma’s substantial on-line sales presence and expands its other on-line websites and its Beyond Human® platform, which currently include over 160 websites and over 2.5 million subscribers.

“We are very excited to announce the official launch of our Amazon®, Walmart®, eBay® and Wish® on-line stores with our current combined 116 product SKUs,” said Innovus CEO Dr. Bassam Damaj. “We are already seeing a significant increase in our month over month sales from the on-line stores and we currently expect the on-line sales to be a growing percentage of our revenues in the very near future.

“In addition, we are working on the development and launch of additional Amazon® sites in Canada, Mexico and the United Kingdom and we look forward to growing our on-line presence of our products and additional products such as Can-C™ and Melatonin (MZS™) that already have large on-line sales presences with Can-C™ alone generating on average across all sellers on Amazon® around $1.2 million per year in 2017. These additional sales channels should only serve to increase the overall sales revenues we may see in the future through our ever-growing online channels,” he continued.

About Can-C™ Eye Drops
Can-C™ eye drops, made by Antiaging Systems, Ltd., are the original N-acetylcarnosine (often shorted to “NAC”) eye drop formula developed to normalize senile cataract impairment.

Users and scientists have reported that Can-C™ is also great for:
Dry eye syndrome.
Benefit for those who wear contact lenses, particularly soft contact lenses. (Not only do the lubricants in Can-C™ help contact lenses feel more comfortable, but N-acetylcarnosine is also believed to inhibit the buildup of lactic acid in the eye, meaning you can wear them in comfort for longer.)

- Corneal disorders.
- Computer vision syndrome.
- Eye strain.
- Ocular inflammation.
- Blurred vision.
- Presbyopia.
- Retinal diseases.
- Vitreous opacities and lesions.
- Complications of diabetes mellitus and other systemic diseases.
- Open-angle primary glaucoma.

Cataract surgery is the most commonly performed operation in the world with over 1.5 million operations in the United States alone every year. Although generally safe, there is still a complication rate of 30% to 50% of patients who develop opacification of the posterior lens capsule within two years and require further laser treatment. Can-C™ cataract eye drops have helped thousands of people normalize their cataracts without surgery, leaving the natural lens in place rather than an artificial one.

Human trials on people suffering from senile cataract, using a twice daily dose of Can-C™ for six months showed the following results:

88.9 percent of patients had improved glare sensitivity;
90 percent reported improved visual acuity – clearer and sharper vision; and
Perhaps most significantly, 41 percent of patients experienced a significant improvement in lens ‘transmissivity.’
And while the patients were taking the NAC carnosine eye drops, the lead researcher noted that there was no recurrence of cataract.

About Melatonin (MZS™)

Melatonin (MZS™) is made by Antiaging Systems Ltd. and its main ingredient, melatonin, is vital to protect a person’s hormonal system, regulate immunity and repair the body’s cells.

It is commonly used by shift workers and also to treat jet lag and age-related sleep disorders, but its abilities go far beyond simply its sleep-inducing properties. Other benefits of the product are its use as an antioxidant, for longevity and for age related macular degenerations.

Melatonin’s effect on longevity is well documented; in fact laboratory tests on rats and mice have demonstrated that melatonin increased their lifespans by 20%. Numerous experts believe melatonin is a vital anti-aging product because of its positive effect on the aging immune system, its protection of the cardiovascular system, its ability to increase growth hormone production and above all its capacity to limit free radical damage.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.

Amazon® is a registered trademark of Amazon.com, Inc. (NASDAQ: AMNZ); eBay® is a registered trademark of eBay, Inc. (NASDAQ: EBAY); Walmart® is a registered trademark of Wal-mart Stores, Inc. (NYSE: WMY); and Wish® is a registered trademark of ContextLogic, Inc.

Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the sales of its products through its Amazon® stores and through its other on-line channels, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Emerging Markets Consulting, LLC
James S. Painter III, 407 340 0226
jamespainter@emergingmarketsllc.com

Source: Innovus Pharmaceuticals, Inc.

Innovus Pharma Hemorrhoid Drug Xyralid™ Receives Approval in Canada

Xyralid™, a Lidocaine-based Cream for the Relief of Pain and Symptoms Caused by Hemorrhoids, is the Sixth Innovus Pharma Product approved in Canada to Date

SAN DIEGO--January 16, 2018 -- Innovus Pharmaceuticals, Inc. (OTCQB: INNV) ("Innovus Pharma" or the “Company”), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the approval of its Product License Application (“PLA”) in Canada for its lidocaine-based cream Xyralid™ (DIN 02471434), for the relief of pain and symptoms caused by hemorrhoids. Xyralid™ will be available as an over-the-counter (“OTC”) or behind the counter drug and will not require a prescription.

“We are very happy that Health Canada has approved our Xyralid™ drug in Canada,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “Xyralid™ is our sixth product on the Canadian market including Zestra®, Zestra Glide® and Uxor™ (EjectDelay™) marketed by Orimed Pharma, UriVarx® through our recently announced partnership with Acerus Pharmaceuticals Corporation and Vesele® through our own marketing and sales efforts in that country. Innovus is expected to launch the product in Canada by the second half of 2018.”

About Xyralid™
Xyralid™ is an FDA-OTC monograph compliant, fast-acting and powerful hemorrhoid anesthetic cream. It contains the active ingredient drug, lidocaine, which provides fast relief for the pain and symptoms caused by hemorrhoids.

Hemorrhoids, also called “piles”, are swollen and inflamed veins in the anus and lower rectum. Hemorrhoids may result from straining during bowel movements or from the increased pressure on these veins during pregnancy, among other causes. Hemorrhoids may be located inside the rectum (internal hemorrhoids) or they may develop under the skin around the anus (external hemorrhoids). There are over 1.2 million hemorrhoid sufferers in Canada making it a very large market1.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.

Innovus Pharma's Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the Xyralid™ drug in Canada if approved in that country, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Emerging Markets Consulting, LLC
James S. Painter III
Tel: +1 407 340 0226
jamespainter@emergingmarketsllc.com

Source: Innovus Pharmaceuticals, Inc.o

Innovus Pharma Announces U.S. Food and Drug Administration Clearance of Its UriVarx® Urinary Tract Infection Test Strips

Company Expects Sales of Its UriVarx® Franchise to Increase With Addition of UTI Test Strips

SAN DIEGO--January 11, 2018 -- Innovus Pharmaceuticals, Inc. (OTCQB: INNV) ("Innovus Pharma" or the “Company”), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its UriVarx® Urinary Tract Infection (“UTI”) test strips under the 510(k) filing of its manufacturing partner, ACON Laboratories, Inc. (“ACON”). Innovus Pharma will offer the recently cleared UriVarx® UTI test strips, which provide results in 2-minutes, to its customers who buy its UriVarx® product. The UTI test strips are complementary to the Company’s UriVarx® supplement currently on the market and clinically tested in patients with overactive bladder (“OAB”) and urinary incontinence (“UI”). The UTI test strips will also be offered separately by Innovus Pharma and are manufactured by ACON. Innovus Pharma currently is expected to launch the UTI strips in Q1 2018.

According to WebMD, UTIs are the most common bacterial infections in the United States. According to a study by the National Institutes of Health in 2007 (NIH publication 075512) by Griebling et al., the prevalence of UTI is found to be higher in women. Nearly 20% of UTIs are found in men. Patients with OAB and UI have a higher occurrence of UTI infections and early detection is key in better responses to treatments.

“We are very pleased that ACON has secured the FDA clearance of the UriVarx® UTI test strips,” stated Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “We look forward to launching the UriVarx® strips with our UriVarx® clinical supplement for bladder health to enable our customers to be able to use our FDA cleared UTI test strips to monitor ongoing bladder infections from the convenience of their homes. We expect the addition of the UTI strips to increase our clinical supplement sales and the average life cycle of our monthly product subscriptions,” he continued.

The Company recently announced the approval of UriVarx® by Health Canada and the signing of a commercial license agreement with Acerus Pharmaceuticals Corporation in Canada for the product.

About UriVarx® Clinical Supplement

UriVarx® is clinically published to reduce urinary urgency, accidents and both day and night frequency in OAB and UI patients.

UriVarx® has undergone two double blind and comparative trials in both male and female OAB and UI patients. The clinical results include:

Reduction of ~56% in Urge Incontinence;
Reduction of ~66% in Stress Incontinence;
Reduction of ~61% in Urinary Urgency;
Reduction of ~33% in Urinary Frequency meaning the total average urinary frequency was in the normal/ideal range after two months of use; and
Reduction of ~46% in Nocturia.
According to the U.S. National Association for Continence (“NAFC”), OAB is a medical term that describes various symptoms caused by involuntary bladder spasms, including urinary frequency, especially at night, and urgency with or without involuntary leakage. These symptoms may occur without obvious cause or be secondary to certain diseases of the nervous system. The NAFC estimates that nearly 25 million Americans suffer from some form of OAB or incontinence. The condition, with frequency and urgency only, affects men and women of all ages, although most are under age 65.

About the UriVarx® FDA Cleared UTI Test

The UriVarx® UTI test strips are FDA-cleared tests for the detection of leukocytes and nitrites to add in the screening of Urinary Tract Infection for self-testing. The test has undergone clinical trials and the results can be seen in two minutes.

According to a study by Grand View Research (April 2016), the market size for urinalysis tests in 2015 worldwide was $1.37 billion and in North America was $510 million of which UTI testing represented a large percentage of that market.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to be a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products, men’s and women’s health supplements, related diagnostics and medical devices. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC, as well as related products.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.

About ACON Laboratories, Inc.
ACON Laboratories Inc. is a privately-owned diagnostics and medical device company, which was founded in 1995, with its headquarters located in San Diego, California. ACON Laboratories, Inc. produces a broad range of medical diagnostic and healthcare products that are sold in over 130 countries worldwide. The company continues to expand its product lines through extensive research and development, with the goal of helping improve the health and well-being of patients around the world. ACON’s manufacturing facility is a US FDA registered manufacturer of rapid diagnostic and healthcare products.

Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the UriVarx® product and the accompanying UTI test strips in the United States if approved in that country, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Emerging Markets Consulting, LLC
James S. Painter III, 407 340 0226
jamespainter@emergingmarketsllc.com

Source: Innovus Pharmaceuticals, Inc.

Innovus Pharma Enters Into License and Distribution Agreement with Acerus Pharmaceuticals for the Commercialization of UriVarx® in Canada

The Company to Receive an Upfront Payment and Minimum Order Quantities at a Pre-Agreed Transfer Price Plus up to CAD$1.65 Million in Sale Milestone Payments

SAN DIEGO--January 8, 2018 -- Innovus Pharmaceuticals, Inc. (OTCQB: INNV) ("Innovus Pharma" or the “Company”), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, today announced that it has entered into an exclusive license and distribution agreement with Acerus Pharmaceuticals Corporation, a Canadian public company (TSX:ASP) (“Acerus”), for its product UriVarx® in Canada. The Agreement with Acerus represents one of the first international license and distribution agreements for Innovus Pharma for one of its core multi-million dollar U.S. products. Under the agreement, Innovus Pharma will receive an up-front license payment and is eligible to receive up to CAD$1.65 million dollars in sales milestone payments plus minimum order quantities at an agreed-upon transfer price.

UriVarx® is a Natural Health Product (NHP) approved by Health Canada that helps reduce symptoms of hyperactive bladder such as daytime urinary frequency, urgency and nocturia. The product will be offered by Acerus over-the-counter to Canadians dealing with such symptoms. Nearly 1 in 5 Canadians over the age of 35 experience overactive bladder symptoms1. Men and women’s lives are directly impacted by an overactive bladder, and the current treatment options may come with systemic side effects.

“We are very excited about this partnership with Acerus,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “They have a great presence in the urology field in Canada, they maintain an active dialogue with Canadian patients and they can leverage their existing salesforce to effectively realize revenues from our core product UriVarx®. We believe that UriVarx® is an innovative NHP with a strong clinical data package that can become a major product in the urology field in Canada.”

“Acerus is very happy to be working with Innovus on the license and distribution of UriVarx® in Canada,” said Tricia Symmes, Chief Operating Officer of Acerus. “Since the product is already approved by Health Canada, the Acerus team expects to launch the product in the second half of 2018 and we expect to potentially generate meaningful revenues this year.”

About UriVarx®
UriVarx® is clinically proven to reduce urinary urgency, accidents and both day and night frequency in Overactive Bladder (“OAB”) and Urinary Incontinence (“UI”) patients. UriVarx® has undergone two double blind and comparative trials in both male and female OAB and UI patients. The clinical results include:

Reduction of ~56% in Urge Incontinence;
Reduction of ~66% in Stress Incontinence;
Reduction of ~61% in Urinary Urgency;
Reduction of ~33% in Urinary Frequency meaning the total average urinary frequency was in the normal/ideal range after two months of use; and
Reduction of ~46% in Nocturia.
According to the Simon Foundation, Urinary Incontinence affects 26 million Americans with a total market size of $1.1 billion (Source: Medical Devices Inc.). The NAFC (National Association for Continence) estimated that over 33 million Americans suffer from Overactive Bladder with a market size over $2.1 billion (Source: IMS Health).

The product is available in the U.S. through www.urivarx.com and through the Beyond Human® print and online platforms.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.

About Acerus
Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve patient experience, with a primary focus in the field of men’s and women’s health. Acerus commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the U.S. and other territories.

Acerus currently has two marketed products: ESTRACE®, a product for the symptomatic relief of menopausal symptoms, is commercialized in Canada; and NATESTO®, the first and only testosterone nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism, is commercialized in Canada and the U.S. In addition, NATESTO® has been licensed for distribution in 30 countries worldwide. Marketing approvals in jurisdictions outside of North America are expected to take place over the course of the coming years. Acerus’ pipeline includes three innovative product lines: GYNOFLOR™, an ultra-low dose vaginal estrogen combined with a probiotic, for which a NDS has been filed in Canada for the treatment of vaginal atrophy, restoration of vaginal flora and treatment of certain vaginal infections; TEFINA™, a clinical stage product aimed at addressing a significant unmet need for women with female sexual dysfunction; and ELEGANTTM, a franchise comprised of ELEGANTTM Vaginal Moisturizer, which provides comfort to women suffering from vaginal dryness, and ELEGANTTM pH, which is a pH balanced vaginal product. Finally, Acerus owns or has a license to numerous patents relating to proprietary delivery systems as well as novel formulations of products currently in the early stage of development.

Acerus’ shares trade on TSX under the symbol ASP. For more information, visit www.aceruspharma.com and follow them on Twitter and LinkedIn.

Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the UriVarx® product in Canada if approved in that country, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

References
1 http://www.canadiancontinence.ca/EN/overactive-bladder-vs-sui.php

Emerging Markets Consulting, LLC
James S. Painter III
407 340 0226
jamespainter@emergingmarketsllc.com

Source: Innovus Pharmaceuticals, Inc.

-------------------------------------------------------------------
About Innovus Pharmaceuticals, Inc.:

About Innovus Pharma
Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

Our Mission Statement
Innovus Pharma's mission is to in-license, acquire or develop over-the-counter and consumer healthcare products designed for in-home treatment of medical conditions and ailments to help people take care of themselves and their families in order to live healthy lives.

Management Team
Bassam Damaj, Ph.D.
President and Chief Executive Officer
Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

Randy Berholtz, MBA/JD
Executive Vice President, Corporate Development and General Counsel
Mr. Randy Berholtz is our Executive Vice President, Corporate Development and General Counsel. He is also the Secretary of the Company. He was the founding partner of the Sorrento Valley Law Group and is the former Executive Vice President, General Counsel and Secretary of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company. Prior to that time, he was the Vice President, General Counsel and Secretary of ACON Laboratories, Inc., a group of Chinese and US life sciences companies. He has also been the Chief Operating Officer and General Counsel of IngleWood Ventures, L.P., a life sciences venture capital company and the Interim General Counsel and Secretary of Nanogen, Inc. (NASDAQ: NGEN), a genomics tools company. He has also been an attorney with the law firms of Heller Ehrman, LLP, Cooley Godward, LLP, Kirkpatrick & Lockhart, LLP (now K&L Gates) and Cravath, Swaine & Moore. He has a Bachelor of Arts degree from Cornell University, a Master of Arts degree from Oxford University, where he was a Rhodes Scholar, and a Juris Doctor degree from Yale Law School where he was a Senior Editor of The Yale Law Journal and an MBA from the University of San Diego School of Business.

Rauly Gutierrez, CPA
Vice President of Finance
Mr. Gutierrez was appointed as our Vice President of Finance on September 23, 2016, and was appointed our Principal Financial and Accounting Officer effective April 24, 2017. He was recently an Audit Senior Manager at KMJ Corbin & Company LLP, a regional public accounting firm. Mr. Gutierrez began his career at KMJ Corbin & Company in 2006 and mainly serviced clients in the pharmaceutical and life science industries which included multiple publicly-traded companies with market caps ranging from $50 million to $2 billion and revenues ranging from pre-revenue to $125 million. He has a wide range of experience dealing with SEC 1933 and 1934 Act filings, including IPOs, reverse mergers, SEC comment letters, Sarbanes-Oxley Act attestation services and periodic SEC reporting requirements. His areas of expertise include complex debt and equity transactions, such as derivatives, convertible instruments, and stock-based compensation. He also has expertise in accounting for gross-to-net revenue recognition for pharmaceutical product sales, pharmacy drug billings and in business combination transactions. Mr. Gutierrez has led several training sessions for audit professionals in professional ethics and independence, PCAOB auditing standards and technical accounting updates. Mr. Gutierrez received his Bachelor of Science Degree in Accounting from the Leventhal School of Accounting at the University of Southern California, and is licensed as a CPA in the State of California. He is also a member of the AICPA, CalCPA and the Association for Corporate Growth.

Robert C. Verfurth
Vice President of Sales and Marketing
Mr. Robert Verfurth came back to Innovus Pharma as our Vice President of Sales and Marketing in June 2017. He spent the previous two years building a commercial team and launching a new blood-based colon cancer technology at Applied Proteomics, Inc. He was also part of the Innovus Pharma team back in 2013 in a similar role. Mr. Verfurth was also part of the marketing and sales team at Apricus Biosciences (NASDAQ: APRI), a specialty pharmaceutical company. Prior to Apricus, Mr. Verfurth was Vice President, US Sales-West for Becton Dickinson Diagnostics. Before that, he served as Vice President, US Sales and Support for the molecular diagnostic start-up GeneOhm Sciences beginning in 2005. GeneOhm Sciences was purchased by Becton Dickinson, after which Mr. Verfurth continued his sales leadership responsibilities in the molecular and infectious disease product areas. Prior to GeneOhm, Mr. Verfurth held a number of commercial roles, including Vice President of Sales at both Prometheus Laboratories and Dianon Systems. He also spent six years in the USAF, achieving a rank of Captain. Mr. Verfurth earned a Bachelor of Science degree in Business Administration from the University of Notre Dame and a Master's of Science degree in Systems Management from the University of Southern California

Innovus Pharma is a leader in OTC and Clinically Proven Consumer Care Products for Men's and Women's Health, Sexual & Reproductive Health, Vitality and Respiratory Disease.
SOURCE: http://licoenergymetals.com/

Disclaimer